ADVERTISEMENT
ADVERTISEMENT
HITLAB, Jeeva partner to advance e-clinical infra
HITLAB will work with Jeeva to synthesize existing platform insights and customer experiences into publishable materials and market-facing narratives.
-
Rwittika Chakraborty
- Mon, 02, Feb 2026
- 01:15 EST
- 13
HITLAB and Jeeva Clinical Trials / hitlab.org/ and jeevatrials.com/
HITLAB, a global healthcare innovation and validation lab, has announced a strategic partnership with Jeeva Clinical Trials, a U.S.-based digital research platform provider delivering a human-centric, AI-native eClinical cloud for decentralized and hybrid clinical trials.
HITLAB, which specializes in regulatory-grade evidence generation, usability testing, and technology assessment for digital health and life sciences companies, works with innovators, health systems, and regulators to accelerate adoption while reducing regulatory and commercial risk.
ALSO READ: VOSAP in tie-up to deliver AI prosthetics to India
With clinical research continuing to shift toward distributed models, sponsors and CROs face growing complexity in deploying AI-enabled infrastructure that is operationally sound, scalable, and accessible to patients.
The partnership brings together Jeeva’s unified eClinical platform and HITLAB’s independent research, validation, and market development expertise to support responsible adoption across the life sciences ecosystem.
Jeeva’s platform allows automated clinical trial workflows and remote participation across multiple therapeutic areas, including oncology and rare diseases.
Through this partnership, HITLAB will support Jeeva’s U.S. growth by independently assessing platform usability and operational fit, strengthening evidence communication, and facilitating strategic engagement with biopharma sponsors, CROs, and investors.
Speaking on this partnership, PhD, Chair and Co-Founder of HITLAB, Stan Kachnowski, said,
“This partnership reflects HITLAB’s commitment to independently evaluating emerging research infrastructure while helping high-potential platforms responsibly scale in the U.S. market.”
PhD, Founder and CEO of Jeeva Clinical Trials, Harsha Rajasimha, also shared his thoughts on the collaboration and said,
“Working with HITLAB allows us to independently validate how our platform performs in real-world research environments while accelerating engagement with sponsors and CROs seeking integrated, AI-enabled solutions that reduce cost and complexity.”
HITLAB will also work with Jeeva to synthesize existing platform insights and customer experiences into publishable materials and market-facing narratives, which will be shared during HITLAB’s May 2026 Innovators Summit in New York City.
Discover more at New India Abroad.
Related
ADVERTISEMENT
ADVERTISEMENT
E Paper
Video
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login